Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lexaria Bioscience Corp. (LEXX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,13, with a market capitalisation of $7,48M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,98 to $23,25. This page covers its latest market performance, valuation, price trends and company information.
$7,48M | |
$3,15 | |
$187,50 | |
$2,98 | |
$3,21 | |
558,00 | |
47,10K | |
-- | |
$23,25 | |
$2,98 | |
-- | |
-- |
Lexaria Bioscience Corp. (LEXX) is trading at $3,13 in pre-market trading as of 2026-09-16 12:17:00, down 2,43% ($0,08) from the previous close of $3,21
Pre-market trading shows how investors are pricing LEXX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Lexaria Bioscience Corp. (LEXX) moved from $14,15 to $3,13, representing a decline of 77,87% ($11,02).
The stock traded between $2,98 and $14,37 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 134,99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,7%
LEXX is currently trading at $3,13, placing it 0,7% of the way from its 52-week low of $2,98 to its 52-week high of $23,25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lexaria Bioscience Corp. (LEXX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.